K. Melbourne

发表

Long-term body composition changes in antiretroviral-treated HIV-infected individuals

A. Collier, D. Kitch, T. Brown, 2016, AIDS.

Patterns of Antiretroviral Therapy Use and Immunologic Profiles at Enrollment in the REPRIEVE Trial.

G. Bloomfield, M. Kozal, K. Tashima, 2020, The Journal of infectious diseases.

Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202.

P. Sax, E. Daar, D. Kitch, 2011, The Journal of infectious diseases.

Cardiovascular Risk and Health Among People With Human Immunodeficiency Virus (HIV) Eligible for Primary Prevention: Insights From the REPRIEVE Trial

G. Bloomfield, C. Fichtenbaum, K. Ruxrungtham, 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Bone mineral density reductions after tenofovir disoproxil fumarate initiation and changes in phosphaturia: a secondary analysis of ACTG A5224s

D. Kitch, T. Brown, G. McComsey, 2017, Journal of Antimicrobial Chemotherapy.

Vitamin D and Calcium Attenuate Bone Loss With Antiretroviral Therapy Initiation

T. Brown, G. McComsey, M. Yin, 2015, Annals of Internal Medicine.

Racial differences in calculated bioavailable vitamin D with vitamin D/calcium supplementation

T. Brown, G. McComsey, M. Yin, 2017, AIDS.

Long-term Bone Mineral Density Changes in Antiretroviral-Treated HIV-Infected Individuals.

A. Collier, D. Kitch, T. Brown, 2016, The Journal of infectious diseases.

Inflammation markers after randomization to abacavir/lamivudine or tenofovir/emtricitabine with efavirenz or atazanavir/ritonavir

P. Sax, E. Daar, D. Kitch, 2012, AIDS.

Peripheral and central fat changes in subjects randomized to abacavir-lamivudine or tenofovir-emtricitabine with atazanavir-ritonavir or efavirenz: ACTG Study A5224s.

P. Sax, E. Daar, D. Kitch, 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Peripheral and Central Fat Changes in Subjects Randomized to Abacavir-Lamivudine or Tenofovir-Emtricitabine With Atazanavir-Ritonavir or Efavirenz : ACTG Study A 5224 s

P. Sax, E. Daar, D. Kitch, 2011 .

Impact of randomized antiretroviral therapy initiation on glucose metabolism

P. Sax, E. Daar, D. Kitch, 2014, AIDS.

Vitamin D does not Modulate Immune-Mediated Bone loss during ART Initiation

T. Brown, M. Yin, K. Melbourne, 2019, Antiviral therapy.

Effects of Antiretroviral Therapy on Immune Function and Arterial Inflammation in Treatment-Naive Patients With Human Immunodeficiency Virus Infection.

Michael T. Lu, G. Robbins, K. Williams, 2016, JAMA cardiology.

P. Sax, E. Daar, D. Kitch, 2011, The Journal of infectious diseases.

Weight and lean body mass change with antiretroviral initiation and impact on bone mineral density

P. Sax, E. Daar, D. Kitch, 2013, AIDS.

Weight Change Following Antiretroviral Therapy Switch in People with Viral Suppression: Pooled Data from Randomized Clinical Trials.

H. Stellbrink, P. Sax, J. Rockstroh, 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Differential Reduction in Monocyte Activation and Vascular Inflammation With Integrase Inhibitor-Based Initial Antiretroviral Therapy Among HIV-Infected Individuals.

M. Lederman, G. McComsey, K. Melbourne, 2015, The Journal of infectious diseases.

Pseudomonas Bacteremia Precipitated by Ticlopidine-Induced Neutropenia

K. Melbourne, S. Geletko, D. Mikolich, 1996, The Annals of pharmacotherapy.

Translating the observed differences in interleukin-6 levels between some antiretroviral regimens into potential long-term risk of serious non-AIDS events: A modeling study

K. Melbourne, J. Baker, C. Cohen, 2022, Frontiers in Immunology.

A PrEP Demonstration Project Using eHealth and Community Outreach to Justice-Involved Cisgender Women and Their Risk Networks

F. Altice, K. Melbourne, Jaimie P. Meyer, 2022, AIDS and Behavior.

HDL Cholesterol Efflux Capacity in Newly Diagnosed HIV and Effects of Antiretroviral Therapy

G. Robbins, K. Williams, T. Burdo, 2017, The Journal of clinical endocrinology and metabolism.

Changes in Proteinuria and Albuminuria With Initiation of Antiretroviral Therapy: Data From a Randomized Trial Comparing Tenofovir Disoproxil Fumarate/Emtricitabine Versus Abacavir/Lamivudine

P. Sax, E. Daar, D. Kitch, 2014, Journal of acquired immune deficiency syndromes.

Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials

H. Stellbrink, P. Sax, J. Rockstroh, 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

The safety and efficacy of granulocyte-macrophage colony-stimulating factor (Sargramostim) added to indinavir- or ritonavir-based antiretroviral therapy: a randomized double-blind, placebo-controlled trial.

J. Bilello, G. Drusano, K. Melbourne, 1999, The Journal of infectious diseases.

Characterization of Rash with Indinavir in a National Patient Cohort

K. Melbourne, A. Grimone, G. J. Vanscoy, 1999, The Annals of pharmacotherapy.

Immunological and Neurometabolite Changes associated with switch from Efavirenz to an Integrase Inhibitor.

Monica L. Bennett, E. Stern, D. Kuritzkes, 2019, Journal of acquired immune deficiency syndromes.

Medication adherence in patients with HIV infection: a comparison of two measurement methods.

K. Melbourne, C. Willey-Lessne, S. Geletko, 1999, The AIDS reader.

Associations of Inflammatory Markers With AIDS and Non-AIDS Clinical Events After Initiation of Antiretroviral Therapy: AIDS Clinical Trials Group A5224s, a Substudy of ACTG A5202

P. Sax, E. Daar, D. Kitch, 2014, Journal of acquired immune deficiency syndromes.

Markers of renal disease and function are associated with systemic inflammation in HIV infection

D. Kitch, G. McComsey, K. Melbourne, 2015, HIV medicine.

Cystatin C-Based Renal Function Changes After Antiretroviral Initiation: A Substudy of a Randomized Trial

P. Sax, E. Daar, D. Kitch, 2014, Open forum infectious diseases.

An immunization update for HIV-infected adults in the United States: review of the literature.

K. Melbourne, J. Larkin, P. Cioe, 2015, The Journal of the Association of Nurses in AIDS Care : JANAC.

Vitamin D Supplementation Does Not Affect Metabolic Changes Seen With ART Initiation

T. Brown, G. McComsey, M. Yin, 2017, Open forum infectious diseases.

Stages of change for adherence with medication regimens for chronic disease: development and validation of a measure.

J. Caro, T. Flanigan, K. Melbourne, 2000, Clinical therapeutics.

Effects of Integrase Inhibitor–Based ART on the NLRP3 Inflammasome Among ART-Naïve People With HIV

G. Robbins, T. Burdo, K. Melbourne, 2020, Open forum infectious diseases.

Successful recruitment of a multi-site international randomized placebo-controlled trial in people with HIV with attention to diversity of race and ethnicity: critical role of central coordination

A. Rancourt, C. Fichtenbaum, P. Douglas, 2020, HIV research & clinical practice.

Assessment of Coronary Artery Disease With Computed Tomography Angiography and Inflammatory and Immune Activation Biomarkers Among Adults With HIV Eligible for Primary Cardiovascular Prevention

Michael T. Lu, C. Fichtenbaum, P. Douglas, 2021, JAMA network open.

Differential Reduction in Monocyte Activation and Vascular Inflammation With Integrase Inhibitor-Based Initial Antiretroviral Therapy Among HIV-Infected Individuals.

M. Lederman, G. McComsey, K. Melbourne, 2015, The Journal of infectious diseases.

Markers of renal disease and function are associated with systemic inflammation in HIV infection

D. Kitch, G. McComsey, K. Melbourne, 2015, HIV medicine.